Valneva (NASDAQ:VALN) Shares Gap Up – Should You Buy?

Valneva SE Sponsored ADR (NASDAQ:VALN) shares gapped up before the market opened on Monday. The stock had previously closed at $5.51, but opened at $5.83. Valneva shares last traded at $5.7840, with a volume of 1,942 shares changing hands.

Wall Street Analyst Weigh In

VALN has been the subject of a number of analyst reports. TD Cowen began coverage on shares of Valneva in a report on Tuesday, August 11th. They set a “buy” rating and a $12.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Valneva in a report on Monday, September 14th. One equities research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and an average target price of $9.30.

Valneva Price Performance

The company has a 50-day moving average price of $6.06 and a 200-day moving average price of $6.76. The firm has a market capitalization of $547.97 million, a P/E ratio of -2.74 and a beta of 1.37. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16.

Valneva (NASDAQ:VALN) last released its earnings results on Friday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The company had revenue of $39.37 million during the quarter, compared to analyst estimates of $44.17 million. Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. On average, sell-side analysts predict that Valneva SE Sponsored ADR will post -1.27 earnings per share for the current year.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases with significant unmet medical needs. The company combines vaccine research and development with in-house manufacturing and commercial operations serving public health agencies, travel medicine providers and private healthcare markets.

Valneva’s marketed products include IXIARO and JESPECT for the prevention of Japanese encephalitis, and DUKORAL, an oral vaccine used to help prevent cholera and, in some markets, enterotoxigenic Escherichia coli-related travelers’ diarrhea.